PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market

7.3 Biomarkers to Predict Responsiveness to Therapy 196 7.3.1 Unmet Need 196 7.3.2 Gap Analysis 198 7.3.3 Opportunity 198 7.4 Early Diagnosis of RA 199 7.4.1 Unmet Need 199 7.4.2 Gap Analysis 200 7.4.3 Opportunity 201 7.5 Personalized Treatment Approach 202 7.5.1 Unmet Need 202 7.5.2 Gap Analysis 202 7.5.3 Opportunity 204 Browse Complete Summary Click Here @ http://www.radiantinsights.com/research/pharmapointrheumatoid-arthritis-global-drug-forecast-and-market-analysis-to-2023 8 Pipeline Assessment 206 8.1 Overview 206 8.2 Clinical Trial Mapping 206 8.2.1 Clinical Trials by Class 206 8.3 Promising Drugs in Clinical Development 208 8.3.1 Sarilumab 215 8.3.2 Sirukumab 223 8.3.3 Clazakizumab 230 8.3.4 Cosentyx (secukinumab) 236 8.3.5 Tregalizumab 242 8.3.6 Mavrilimumab 248 8.3.7 Denosumab (Prolia/Xgeva) 253

PharmaPoint Rheumatoid Arthritis - Drug Forecast and Market PharmaPoint Rheumatoid Arthritis - Drug Market | Page 7